Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer

Cancer Genomics and Proteomics

Volumn 10, Issue 1, 2013, Pages 27-34

  Skirnisdottir, Ingiridur ^a   Seidal, Tomas ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b HALMSTAD HOSPITAL   (Sweden)

Author keywords

Cyclin kinase inhibitors; Histological subtypes; Ovarian cancer; P21; P21 P53; P21P27.; Prognosis

Indexed keywords

PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PREDICTIVE VALUE; PROTEIN ANALYSIS; SURVIVAL RATE; TUMOR RECURRENCE;

EID: 84875035897     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Zagouri F, Dimopoulos MA, Bournakis E and Papadimitriou CA: Molecular markers in epithelial ovarian cancer: Their role in prognosis and therapy. Eur J Gynaecol Oncol 31(3): 268-277, 2010.
2. Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS and Bell J: Survival after recurrence in early-stage high-risk epithelial ovarian cancer: Gynecologic Oncology Group study. Gynecol Oncol 116(3): 307-311, 2010.
3. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB and Huntsman D. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Medicine 5(12): 1749-1760, 2008.
4. Belt EJ, Brosens RP, Delis-van Diemen PM, Bril H, Tijssen M, van Essen DF, Heymans MW, Belien JA, Stockmann HB, Meijer S and Meijer GA: Cell cycle proteins predict recurrence in stage II and III colon cancer. Ann Surg Oncol, DOI 10.1245/s10434-012-2216-7, 2012.
5. Le Page C, Huntsman DG, Provencher DM and Mes-Masson AM: Predictive and prognostic protein biomarkers in epithelial ovarian cancer: Recommendation for future studies. Cancers 2(2): 913-954, 2010.
6. Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF and Henshall SM: Cyclin D1, p53, and p21 Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10(15): 5168-5177, 2004.
7. Milde-Langosch K and Riethdorf S: Role of cell-cycle regulatory proteins in gynecological cancer. J Cellular Phys 196(2): 224-244, 2003.
8. He G, Kuang J, Huang Z, Koomen J, Kobayashi R, Khokhar AR and Siddik ZH: Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer 95(11): 1514-1524, 2006.
9. Green JA, Berns EMJJ, Coens C, van Luijk I, Thompson-Hehir J, van Diest P, Verheijen RHM, van de Vijver M, van Dam P, Kenter GG, Tjalma W, Ewing PC, Teodorovic I, Vergote I and van der Burg M EL: Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer Group (study 55865). Eur J Cancer 42(15): 2539-2548, 2006.
10. Gartel AL and Radhakrishnan SK: Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65(10): 3980-3985, 2005.
11. Buchynska LG and Nesina IP: Expression of the cell cycle regulators p53, p21WAF1/CIP1 and p16INK4A in human endometrial adenocarcinoma. Exper Oncol 28(2): 152-155, 2006.
12. Anttila MA, Kosma V-M, Hongxiu J, Puolakka J, Juhola M, Saarikoski S and Syrjänen K: p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 79(11/12): 1870-1878, 1999.
13. Geisler HE, Geisler JP, Miller GA, Geisler MJ, Wiemann MC, Zhou Z and Crabtree W: p21 and p53 in ovarian carcinoma: Their combined staining is more valuable than either alone. Cancer 92(4): 781-786, 2001.
14. Schmider-Ross A, Pirsig O, Gottschalk E, Denkert C, Lichtenegger W and Reles A: Cyclin-dependent kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer. J Cancer Res Clin Oncol 132(3): 163-170, 2006.
15. Plisiecka-Halasa J: P21 WAF1, P27 KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Ann Oncol 14(7): 1078-1085, 2003. http://www.wma.net/en/30publications/10policies/b3/index.html.
16. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L and Timmers P, Coens C and Pecorelli S: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 95(2): 113-125, 2003.
17. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7): 844-847, 1998.
18. Seidal T, Balaton AJ and Battifora H: Interpretation and quantification of immunostains. Am J Surg Pathol 25(9): 1204-1207, 2001.
19. Skirnisdottir IA, Sorbe B, Lindborg K and Seidal T: Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer 21(2): 236-244, 2011.
20. Köbel M KS, Huntsman DG, Santos J, Swenerton KD, Seidman JD and Gilks CB: Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29: 203-2011, 2010.
21. Saegusa M, Machida DB andOkayasu I: Possible Associations among Expression of p14 ARF,p16 INK4a, p21 WAF1/CIP1, p27 KIP1 and p53 Accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas. Cancer 92(5): 1177-1189, 2001.
22. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J and Birrer MJ: Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11(18): 6422-6430, 2005.
23. Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, Cho SH and An HJ: Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Int J Gynecol Pathol 30(3): 205-217, 2011.
24. Rose SL, Goodheart MJ, DeYoung BR, Smith BJ and Buller RE: p21 expression predicts outcome in p53 null ovarian carcinoma. Clin Cancer Res 9: 1028-1032, 2003.
25. Kobel M, Reuss A, Bois A, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG and Gilks CB: The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 222(2): 191-198, 2010.
26. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih Ie M and Kurman RJ: Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: An immunohistochemical and nucleotide sequencing analysis. Mod Pathol 24(9): 1248-1253, 2011.
27. de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, van der Zee AG and de Bock GH: Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: A meta-analysis. Br J Cancer 101(1): 149-159, 2009.
28. Korkolopoulou P, Vassilopoulos I, Konstantinidou AE, Zorzos H, Patsouris E, Agapitos E and Davaris P: The Combined Evaluation of p27 Kip1 and Ki-67 Expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol Oncol 85(3): 404-414, 2002.
29. G Ferrandina AS, Fagotti A, Fanfani F, Sacco R, De Pasqua A, Mancuso S and Scambia G: p21 WAF1/CIP1 protein expression in primary ovarian cancer. Int J Oncol 17(6): 1231-1236, 2000.
30. Werness BA, Freedman AN, PiverS, Romero-Gutierrez M, and Petrow E: Prognostic Significance of p53 and p21 waf1/cip1 Immunoreactivity in epithelial cancers of the ovary. Gynecol Oncol 75: 413-418, 1999.
31. Gallagher MF, Heffron CC, Laios A, O'Toole SA, Ffrench B, Smyth PC, Flavin RJ, Elbaruni SA, Spillane CD, Martin CM, Sheils OM and O'Leary JJ: Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples. J Ovar Res 5(1): 2, 2012.
32. Berry NB and Bapat SA: Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. J Ovar Res 1: 8, 2008.
33. McCluggage: Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogene. Pathol 43(5): 420-432, 2011.